SLC5A2 and diabetes mellitus: It has also been reported that reductions in glomerular pressure with SGLT2 inhibitor treatment are reflected by an initial dip in the eGFR and reductions in albuminuria (proteinuria) in clinical trials regardless of the presence/absence of diabetes [2,3,4].